Double robust estimator of average causal treatment effect for censored medical cost data

In observational studies, estimation of average causal treatment effect on a patient's response should adjust for confounders that are associated with both treatment exposure and response. In addition, the response, such as medical cost, may have incomplete follow‐up. In this article, a double robust estimator is proposed for average causal treatment effect for right censored medical cost data. The estimator is double robust in the sense that it remains consistent when either the model for the treatment assignment or the regression model for the response is correctly specified. Double robust estimators increase the likelihood the results will represent a valid inference. Asymptotic normality is obtained for the proposed estimator, and an estimator for the asymptotic variance is also derived. Simulation studies show good finite sample performance of the proposed estimator and a real data analysis using the proposed method is provided as illustration. Copyright © 2016 John Wiley & Sons, Ltd.     

Instrumental variable with competing risk model

In this paper, we discuss causal inference on the efficacy of a treatment or medication on a time‐to‐event outcome with competing risks. Although the treatment group can be randomized, there can be confoundings between the compliance and the outcome. Unmeasured confoundings may exist even after adjustment for measured covariates. Instrumental variable methods are commonly used to yield consistent estimations of causal parameters in the presence of unmeasured confoundings. On the basis of a semiparametric additive hazard model for the subdistribution hazard, we propose an instrumental variable estimator to yield consistent estimation of efficacy in the presence of unmeasured confoundings for competing risk settings. We derived the asymptotic properties for the proposed estimator. The estimator is shown to be well performed under finite sample size according to simulation results. We applied our method to a real transplant data example and showed that the unmeasured confoundings lead to significant bias in the estimation of the effect (about 50% attenuated). Copyright © 2017 John Wiley & Sons, Ltd.     

Inference for the median residual life function in sequential multiple assignment randomized trials

In survival analysis, median residual lifetime is often used as a summary measure to assess treatment effectiveness; it is not clear, however, how such a quantity could be estimated for a given dynamic treatment regimen using data from sequential randomized clinical trials. We propose a method to estimate a dynamic treatment regimen‐specific median residual life (MERL) function from sequential multiple assignment randomized trials. We present the MERL estimator, which is based on inverse probability weighting, as well as, two variance estimates for the MERL estimator. One variance estimate follows from Lunceford, Davidian and Tsiatis' 2002 survival function‐based variance estimate and the other uses the sandwich estimator. The MERL estimator is evaluated, and its two variance estimates are compared through simulation studies, showing that the estimator and both variance estimates produce approximately unbiased results in large samples. To demonstrate our methods, the estimator has been applied to data from a sequentially randomized leukemia clinical trial. Copyright © 2013 John Wiley & Sons, Ltd.     

Smoothed time-dependent receiver operating characteristic curve for right censored survival data

The prediction reliability is of primary concern in many clinical studies when the objective is to develop new predictive models or improve existing risk scores. In fact, before using a model in any clinical decision making, it is very important to check its ability to discriminate between subjects who are at risk of, for example, developing certain disease in a near future from those who will not. To that end, the time-dependent receiver operating characteristic (ROC) curve is the most commonly used method in practice. Several approaches have been proposed in the literature to estimate the ROC nonparametrically in the context of survival data. But, except one recent approach, all the existing methods provide a nonsmooth ROC estimator whereas, by definition, the ROC curve is smooth. In this article we propose and study a new nonparametric smooth ROC estimator based on a weighted kernel smoother. More precisely, our approach relies on a well-known kernel method used to estimate cumulative distribution functions of random variables with bounded supports. We derived some asymptotic properties for the proposed estimator. As bandwidth is the main parameter to be set, we present and study different methods to appropriately select one. A simulation study is conducted, under different scenarios, to prove the consistency of the proposed method and to compare its finite sample performance with a competitor. The results show that the proposed method performs better and appear to be quite robust to bandwidth choice. As for inference purposes, our results also reveal the good performances of a proposed nonparametric bootstrap procedure. Furthermore, we illustrate the method using a real data example.     

CROSS-OVER TRIALS WITH CENSORED DATA

Cross-over trials assign two or more treatments sequentially to the same subject; groups of subjects receive different treatment sequences. Both parametric and non-parametric methods of inference are available for cross-over trials with complete data. In this paper we develop methods for estimation and testing in cross-over trials with censored data, based partly on methods used for complete data. Our estimator is consistent for the true effects. Simulation results show that both of our proposed tests have approximately nominal size. We compare our procedures to a method for cross-over designs based on Cox regression proposed by France, Lewis and Kay. We demonstrate that our method of estimation is superior to the Cox-based method, which has considerable bias. Both of the tests presented here have more power than the Cox-based tests in all of the situations we investigated. The estimation and test procedures apply to other designs, such as parallel trials and repeated measures designs.     

Doubly robust estimation and causal inference for recurrent event data

Many longitudinal databases record the occurrence of recurrent events over time. In this article, we propose a new method to estimate the average causal effect of a binary treatment for recurrent event data in the presence of confounders. We propose a doubly robust semiparametric estimator based on a weighted version of the Nelson-Aalen estimator and a conditional regression estimator under an assumed semiparametric multiplicative rate model for recurrent event data. We show that the proposed doubly robust estimator is consistent and asymptotically normal. In addition, a model diagnostic plot of residuals is presented to assess the adequacy of our proposed semiparametric model. We then evaluate the finite sample behavior of the proposed estimators under a number of simulation scenarios. Finally, we illustrate the proposed methodology via a database of circus artist injuries.     

An analytic method for the placebo‐based pattern‐mixture model

Pattern‐mixture models provide a general and flexible framework for sensitivity analyses of nonignorable missing data. The placebo‐based pattern‐mixture model (Little and Yau, Biometrics 1996; 52 :1324–1333) treats missing data in a transparent and clinically interpretable manner and has been used as sensitivity analysis for monotone missing data in longitudinal studies. The standard multiple imputation approach (Rubin, Multiple Imputation for Nonresponse in Surveys, 1987) is often used to implement the placebo‐based pattern‐mixture model. We show that Rubin's variance estimate of the multiple imputation estimator of treatment effect can be overly conservative in this setting. As an alternative to multiple imputation, we derive an analytic expression of the treatment effect for the placebo‐based pattern‐mixture model and propose a posterior simulation or delta method for the inference about the treatment effect. Simulation studies demonstrate that the proposed methods provide consistent variance estimates and outperform the imputation methods in terms of power for the placebo‐based pattern‐mixture model. We illustrate the methods using data from a clinical study of major depressive disorders. Copyright © 2013 John Wiley & Sons, Ltd.     

Estimation of average treatment effect with incompletely observed longitudinal data: Application to a smoking cessation study

We study the problem of estimation and inference on the average treatment effect in a smoking cessation trial where an outcome and some auxiliary information were measured longitudinally, and both were subject to missing values. Dynamic generalized linear mixed effects models linking the outcome, the auxiliary information, and the covariates are proposed. The maximum likelihood approach is applied to the estimation and inference on the model parameters. The average treatment effect is estimated by the G‐computation approach, and the sensitivity of the treatment effect estimate to the nonignorable missing data mechanisms is investigated through the local sensitivity analysis approach. The proposed approach can handle missing data that form arbitrary missing patterns over time. We applied the proposed method to the analysis of the smoking cessation trial. Copyright © 2009 John Wiley & Sons, Ltd.     

Estimating the mean hazard ratio parameters for clustered survival data with random clusters

We consider a latent variable hazard model for clustered survival data where clusters are a random sample from an underlying population. We allow interactions between the random cluster effect and covariates. We use a maximum pseudo-likelihood estimator to estimate the mean hazard ratio parameters. We propose a bootstrap sampling scheme to obtain an estimate of the variance of the proposed estimator. Application of this method in large multi-centre clinical trials allows one to assess the mean treatment effect, where we consider participating centres as a random sample from an underlying population. We evaluate properties of the proposed estimators via extensive simulation studies. A real data example from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention Trial illustrates the method. © 1997 by John Wiley & Sons, Ltd.     

Doubly robust inference for targeted minimum loss–based estimation in randomized trials with missing outcome data

Missing outcome data is a crucial threat to the validity of treatment effect estimates from randomized trials. The outcome distributions of participants with missing and observed data are often different, which increases bias. Causal inference methods may aid in reducing the bias and improving efficiency by incorporating baseline variables into the analysis. In particular, doubly robust estimators incorporate 2 nuisance parameters: the outcome regression and the missingness mechanism (ie, the probability of missingness conditional on treatment assignment and baseline variables), to adjust for differences in the observed and unobserved groups that can be explained by observed covariates. To consistently estimate the treatment effect, one of these nuisance parameters must be consistently estimated. Traditionally, nuisance parameters are estimated using parametric models, which often precludes consistency, particularly in moderate to high dimensions. Recent research on missing data has focused on data‐adaptive estimation to help achieve consistency, but the large sample properties of such methods are poorly understood. In this article, we discuss a doubly robust estimator that is consistent and asymptotically normal under data‐adaptive estimation of the nuisance parameters. We provide a formula for an asymptotically exact confidence interval under minimal assumptions. We show that our proposed estimator has smaller finite‐sample bias compared to standard doubly robust estimators. We present a simulation study demonstrating the enhanced performance of our estimators in terms of bias, efficiency, and coverage of the confidence intervals. We present the results of an illustrative example: a randomized, double‐blind phase 2/3 trial of antiretroviral therapy in HIV‐infected persons.     

A test for the correct specification of marginal structural models

Marginal structural models (MSMs) allow estimating the causal effect of a time-varying exposure on an outcome in the presence of time-dependent confounding. The parameters of MSMs can be estimated utilizing an inverse probability of treatment weight estimator under certain assumptions. One of these assumptions is that the proposed causal model relating the outcome to exposure history is correctly specified. However, in practice, the true model is unknown. We propose a test that employs the observed data to attempt validating the assumption that the model is correctly specified. The performance of the proposed test is investigated with a simulation study. We illustrate our approach by estimating the effect of repeated exposure to psychosocial stressors at work on ambulatory blood pressure in a large cohort of white-collar workers in Québec City, Canada. Code examples in SAS and R are provided to facilitate the implementation of the test.     

Semiparametric ROC surfaces for continuous diagnostic tests based on two test measurements

We propose a semiparametric method for estimating ROC surfaces for continuous diagnostic tests based on two test measurements. Such a three‐class diagnostic problem based on two test measurements arises naturally from some DNA amplification‐related diagnostic scenarios. Simulation results show that our proposed semiparametric ROC surface estimator is more efficient than the nonparametric counterpart and is quite comparable with the parametric counterpart when model assumption of the data is correctly specified for the parametric method. Moreover, when the parametric model assumption is not true, our proposed semiparametric method is superior to both nonparametric and parametric methods. Some discussions and a simulated example along with R programs for implementation of the proposed method are also provided. Copyright © 2009 John Wiley & Sons, Ltd.     

Leveraging prognostic baseline variables to gain precision in randomized trials

We focus on estimating the average treatment effect in a randomized trial. If baseline variables are correlated with the outcome, then appropriately adjusting for these variables can improve precision. An example is the analysis of covariance (ANCOVA) estimator, which applies when the outcome is continuous, the quantity of interest is the difference in mean outcomes comparing treatment versus control, and a linear model with only main effects is used. ANCOVA is guaranteed to be at least as precise as the standard unadjusted estimator, asymptotically, under no parametric model assumptions and also is locally semiparametric efficient. Recently, several estimators have been developed that extend these desirable properties to more general settings that allow any real‐valued outcome (e.g., binary or count), contrasts other than the difference in mean outcomes (such as the relative risk), and estimators based on a large class of generalized linear models (including logistic regression). To the best of our knowledge, we give the first simulation study in the context of randomized trials that compares these estimators. Furthermore, our simulations are not based on parametric models; instead, our simulations are based on resampling data from completed randomized trials in stroke and HIV in order to assess estimator performance in realistic scenarios. We provide practical guidance on when these estimators are likely to provide substantial precision gains and describe a quick assessment method that allows clinical investigators to determine whether these estimators could be useful in their specific trial contexts. Copyright © 2015 John Wiley & Sons, Ltd.     

A flexible mixed‐effect negative binomial regression model for detecting unusual increases in MRI lesion counts in individual multiple sclerosis patients

We develop a new modeling approach to enhance a recently proposed method to detect increases of contrast‐enhancing lesions (CELs) on repeated magnetic resonance imaging, which have been used as an indicator for potential adverse events in multiple sclerosis clinical trials. The method signals patients with unusual increases in CEL activity by estimating the probability of observing CEL counts as large as those observed on a patient's recent scans conditional on the patient's CEL counts on previous scans. This conditional probability index (CPI), computed based on a mixed‐effect negative binomial regression model, can vary substantially depending on the choice of distribution for the patient‐specific random effects. Therefore, we relax this parametric assumption to model the random effects with an infinite mixture of beta distributions, using the Dirichlet process, which effectively allows any form of distribution. To our knowledge, no previous literature considers a mixed‐effect regression for longitudinal count variables where the random effect is modeled with a Dirichlet process mixture. As our inference is in the Bayesian framework, we adopt a meta‐analytic approach to develop an informative prior based on previous clinical trials. This is particularly helpful at the early stages of trials when less data are available. Our enhanced method is illustrated with CEL data from 10 previous multiple sclerosis clinical trials. Our simulation study shows that our procedure estimates the CPI more accurately than parametric alternatives when the patient‐specific random effect distribution is misspecified and that an informative prior improves the accuracy of the CPI estimates. Copyright © 2015 John Wiley & Sons, Ltd.     

A refined method for the meta-analysis of controlled clinical trials with binary outcome.

For the meta-analysis of controlled clinical trials with binary outcome a test statistic for testing an overall treatment effect is proposed, which is based on a refined estimator for the variance of the treatment effect estimator usually used in the random-effects model of meta-analysis. In simulation studies it is shown that the proposed test keeps the prescribed significance level much better than the commonly used tests in the fixed-effects and random-effects model, respectively. Moreover, when using the test it is not necessary to choose between fixed effects and random effects approaches in advance. The proposed method applies in the same way to the analysis of a controlled multi-centre study with binary outcome, including a possible interaction between drugs and centres.     

Estimation of treatment effect under non‐proportional hazards and conditionally independent censoring

In clinical trials with time‐to‐event outcomes, it is common to estimate the marginal hazard ratio from the proportional hazards model, even when the proportional hazards assumption is not valid. This is unavoidable from the perspective that the estimator must be specified a priori if probability statements about treatment effect estimates are desired. Marginal hazard ratio estimates under non‐proportional hazards are still useful, as they can be considered to be average treatment effect estimates over the support of the data. However, as many have shown, under non‐proportional hazard, the ‘usual’ unweighted marginal hazard ratio estimate is a function of the censoring distribution, which is not normally considered to be scientifically relevant when describing the treatment effect. In addition, in many practical settings, the censoring distribution is only conditionally independent (e.g., differing across treatment arms), which further complicates the interpretation. In this paper, we investigate an estimator of the hazard ratio that removes the influence of censoring and propose a consistent robust variance estimator. We compare the coverage probability of the estimator to both the usual Cox model estimator and an estimator proposed by Xu and O'Quigley (2000) when censoring is independent of the covariate. The new estimator should be used for inference that does not depend on the censoring distribution. It is particularly relevant to adaptive clinical trials where, by design, censoring distributions differ across treatment arms. Copyright © 2012 John Wiley & Sons, Ltd.     

A method for the analysis of repeated binary outcomes in randomized clinical trials with non-compliance

When analysing repeated binary data from randomized trials, the model-based approaches, such as generalized estimating equations, are frequently used. Such methods ignore compliance information and give the model-based intention-to-treat estimate of treatment effect. In this paper, the design-based (randomization-based) semi-parametric estimation procedure is given in the estimation of causal risk difference. The resulting risk difference estimator is interpreted as an extension of the instrumental variables estimator for a binary outcome which has the causal interpretation. Extension of the proposed method to stratified analysis is given for data from stratified randomization or meta-analysis. It yields a Mantel-Haenszel type risk difference estimator. As a special case of stratified analysis, the pattern mixture model which stratifies the data by pattern of missing data is performed. Application of the proposed method to a trial in which endpoints were the occurrences of fever over three courses is provided. The same ideas are applied to the causal risk ratio estimation.     

An alternative empirical likelihood method in missing response problems and causal inference

Missing responses are common problems in medical, social, and economic studies. When responses are missing at random, a complete case data analysis may result in biases. A popular debias method is inverse probability weighting proposed by Horvitz and Thompson. To improve efficiency, Robins et al. proposed an augmented inverse probability weighting method. The augmented inverse probability weighting estimator has a double‐robustness property and achieves the semiparametric efficiency lower bound when the regression model and propensity score model are both correctly specified. In this paper, we introduce an empirical likelihood‐based estimator as an alternative to Qin and Zhang (2007). Our proposed estimator is also doubly robust and locally efficient. Simulation results show that the proposed estimator has better performance when the propensity score is correctly modeled. Moreover, the proposed method can be applied in the estimation of average treatment effect in observational causal inferences. Finally, we apply our method to an observational study of smoking, using data from the Cardiovascular Outcomes in Renal Atherosclerotic Lesions clinical trial. Copyright © 2016 John Wiley & Sons, Ltd.     

A marginal estimate for the overall treatment effect on a survival outcome within the joint modeling framework

Joint models for longitudinal and survival data are increasingly used and enjoy a wide range of application areas. In this article, we focus on the application of joint models on clinical trial data with special interest in the treatment effect on the survival outcome. Within a joint model, the estimated treatment effect on the survival outcome is an aggregate comprising the indirect treatment effect through the longitudinal outcome and the direct treatment effect on the survival outcome. This overall treatment effect is, however, conditional on random effects, and therefore has a subject-specific interpretation. The conditional interpretation arises from the shared random effects between the longitudinal and survival process in combination with the nonlinear link function of the survival model. The overall treatment effect is, therefore, not valid for population-based inference, which is the goal for most clinical trials. We propose a method to obtain a marginal estimate of the overall treatment effect on the survival outcome in a joint model. Additionally, we extend our proposal to allow for different parameterizations for the association between the longitudinal and survival outcome. The proposed method is demonstrated on data of a clinical study on the effect of synbiotic on the gut microbiota of cesarean delivered infants, where we estimate the marginal overall treatment effect on the risk of eczema or atopic dermatitis using longitudinal information on fecal bifidobacteria.     

Blinded assessment of treatment effects utilizing information about the randomization block length

It is essential for the integrity of double‐blind clinical trials that during the study course the individual treatment allocations of the patients as well as the treatment effect remain unknown to any involved person. Recently, methods have been proposed for which it was claimed that they would allow reliable estimation of the treatment effect based on blinded data by using information about the block length of the randomization procedure. If this would hold true, it would be difficult to preserve blindness without taking further measures. The suggested procedures apply to continuous data. We investigate the properties of these methods thoroughly by repeated simulations per scenario. Furthermore, a method for blinded treatment effect estimation in case of binary data is proposed, and blinded tests for treatment group differences are developed both for continuous and binary data. We report results of comprehensive simulation studies that investigate the features of these procedures. It is shown that for sample sizes and treatment effects which are typical in clinical trials, no reliable inference can be made on the treatment group difference which is due to the bias and imprecision of the blinded estimates. Copyright © 2009 John Wiley & Sons, Ltd.